K. Ellison

发表

Comprehensive Immune Profiling of Medullary Thyroid Cancer.

F. Hirsch, B. Haugen, C. Rivard, 2020, Thyroid : official journal of the American Thyroid Association.

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation

F. Hirsch, T. Mitsudomi, Jihye Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

S. Leong, T. Pitts, A. Hansen, 2018, Cancer research.

LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Medical science monitor : international medical journal of experimental and clinical research.

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

F. Hirsch, C. Rivard, Hui Yu, 2016, Cancer science.

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

F. Hirsch, D. Gao, C. Rivard, 2018, Lung cancer.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

M. Kris, G. Sica, I. Wistuba, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

MHC class II expression in lung cancer.

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Lung cancer.

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

F. Hirsch, T. Mitsudomi, K. Politi, 2017, BioMed research international.

PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines: Topic: Pathology

F. Hirsch, D. Gao, C. Rivard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Immune Proﬁling of Medullary Thyroid Cancer

F. Hirsch, B. Haugen, C. Rivard, 2020 .

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

F. Hirsch, T. Mitsudomi, Jihye Kim, 2018, Molecular Cancer Therapeutics.

PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, D. Gao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Loss of STING expression is prognostic in non–small cell lung cancer

F. Hirsch, R. Dziadziuszko, Z. Lohinai, 2022, Journal of surgical oncology.

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer

F. Hirsch, Y. Yatabe, T. Boyle, 2014, Clinical lung cancer.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

F. Hirsch, T. Mitsudomi, K. Politi, 2017, Lung cancer.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions with EGFR Mutation

F. Hirsch, T. Mitsudomi, C. Rivard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Simion I. Chiosea, G. Mills, A. Jimeno, 2017, JCI insight.

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

F. Hirsch, T. Mitsudomi, C. Rivard, 2017, PloS one.

EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

F. Hirsch, C. Rivard, Hui Yu, 2019, Cancer treatment reviews.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer

F. Hirsch, M. Varella‐Garcia, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer: Topic: Pathology

F. Hirsch, T. Mitsudomi, Jihye Kim, 2017 .

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

S. Leong, T. Pitts, A. Hansen, 2018, Cancer research.

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

T. Mitsudomi, Jihye Kim, C. Rivard, 2018, Molecular Cancer Therapeutics.